Tehran(IP)- The Chairman of the Execution of Imam Khomeini's Order (EIKO) stressed that Iran had commenced its first phase of COVID-19 vaccine mass production with a capacity of 3 million doses per month on March 14, 2021.

Iran Press/Iran News: In response to IP on the latest measures taken by the Execution of Imam Khomeini's Order (EIKO), Mohammad Mokhber said that the second phase of COVID-19 vaccine mass production with a capacity of 12-15 million doses per month was scheduled to be operational by the end of June.

Mokhber added that the Execution of Imam Khomeini's Order (EIKO) was expected to operate the Iranian-made COVID-19 vaccine mass production with a capacity of 15-20 million doses per month by the end of spring.

The Chairman of the (EIKO) also highlighted the ways how all the international health protocols and standards were observed and applied in all vaccine-production processes.

Mokhber underlined that various world countries, including the Islamic Republic of Iran, had made nonstop efforts to develop the COVID-19 vaccine some of which were at the human trial phase, fortunately. 

Phases 2 and 3 of the first Iranian COVID-19 vaccine's clinical trial started this morning (Monday) at Eram Hotel in Tehran with the chairman of Execution of Imam Khomeini's Order in attendance.

214/216

Read more:

2nd, 3rd phases of COVIran Barekat vaccine's clinical trial kicks off

Iran injects second dose of COVID vaccine in Qazvin's Buali Sina Hospital